Pricing Log in Create free account
Friday 6 November 2026 Export SBFM’s income statement to Excel — free account

Sunshine Biopharma, Inc.

SBFM Healthcare Drug Manufacturers Specialty & Generic

Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024.

Revenue
−1.56%
EPS
+70.9%
Free cash flow
+49.4%

Quarter to June 2026, against a year earlier

2.76 0.03 −1.08%
Market cap
$2.1M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
4/9
Altman Z
−1.72
Beneish M
−2.96
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 2.13
Revenue ttm 35.35
Net income ttm (5.83)
Free cash flow ttm (5.54)
Net debt Q (13.75)
Valuation
P/E 0.00
Forward P/E (0.08) (negative: loss-making)
Price / sales 0.01
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.01
Financial health
Current ratio Q 5.46 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 51.28
Growth
Revenue growth Q −1.56% (below 0%: shrinking)
Operating income growth Q +21.50% (above 0%: growing)
EPS, this year +86.46% (at or above 15%: strong)
EPS, next year A +79.49% (at or above 15%: strong)
Revenue, next year A +1.22%
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.3×, against a ten-year median of 0.0×; over the ten years it ranged from −1.8× in 2023 to 473,438,832× in 2020.
P/S against its own 10 years 2.41%
10-year low 10-year high
P/B against its own 10 years 3.36%
10-year low 10-year high
EV/FCF against its own 10 years 93.92%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 16 10 9 14
Receivables 3 4 3 4
Inventory 6 11 13 12
Other — — — 0
25 26 27 31
2023 2024 2025 Q'26
Payables 3 6 6 5
ST’ Debt — — — —
Other — — — —
6 6 6 6

Compound Annual Growth %

10y 5y 3y
Sales — 247.74% 102.91%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 2.13%

EPS $

Mar Jun Sep Dec Year
’26 (50.71) (22.91) — — —
’25 (87.28) (78.77) (38.80) (82.62) (287.48)
’24 (400.00) (1.99k) (188.93) 1.11k (1.46k)
’23 (1.60k) (400.00) (800.00) (15.06k) (3.51k)
’22 (0.23) (0.03) (0.08) (1.42) (1.76)
’21 (2.82) (1.20) (1.59) 0.85 (4.76)
’20 0.00 (0.01) 0.00 (2.72) (2.73)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 8 9 — — —
’25 9 9 9 9 36
’24 8 9 8 10 35
’23 5 6 6 8 24
’22 0 0 0 4 4
’21 0 0 0 0 0
’20 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (1) — — —
’25 (2) (1) (1) (2) (5)
’24 (3) (5) (1) (3) (13)
’23 (2) (4) 0 (3) (9)
’22 (1) (1) (1) (2) (5)
’21 0 (1) (1) 0 (2)
’20 0 0 0 0 (1)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (1) — — —
’25 (2) (2) (1) (2) (6)
’24 (4) (5) (2) (4) (15)
’23 (2) (4) 0 (3) (10)
’22 (1) (1) (1) (3) (6)
’21 0 (1) (1) 0 (2)
’20 0 0 0 0 (1)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 0 0 0 4 24 35 36 35 +246.2% 37 45 — +11.3%
Gross margin, % 0.00 0.00 0.00 47.87 63.87 48.42 39.04 34.61 30.60 33.76 30.30 +33.8 pt
EBT (3) (1) (2) (1) (3) (12) (27) (4) (5) (6) (6) +6.1%
EBT margin, % 0.00 0.00 0.00 (5,109.48) (3,899.30) (5,445.05) (610.07) (17.06) (15.40) (16.40) (15.73) (16.4) pt
Net income (3) (1) (2) (2) (3) (12) (27) (5) (5) (6) (6) +6.1%
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.07 0.09 0.29 240,928.00 9,964.09 1,745.48 517.52 n/m
Earnings (0.01) (0.02) (0.71) (0.15) (2.73) (4.76) (1.76) (3,513.48) (1,463.23) (287.48) (195.04) +219.9%
Cash flow 0.00 (0.01) (0.17) (0.05) (0.64) (0.70) (0.35) (87,751.00) (3,578.51) (256.30) (78.37) +315.1%
Capex 0.00 0.00 (0.01) 0.00 0.00 0.00 (0.02) (7,881.00) (565.54) (40.21) (2.69) n/m
Free cash flow 0.00 (0.01) (0.17) (0.05) (0.65) (0.70) (0.37) (95,632.00) (4,144.06) (296.51) (81.06) +321.9%
Book value 0.00 (0.01) (0.02) (0.07) (0.94) 0.08 1.42 212,074.00 6,714.51 1,107.62 403.19 n/m
Shares, m 425 44 3 11 1 3 15 0 0 0 0 (66.8%)
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — 18,653,118.48 897,142.86 2,672,584.68 1,041,062.71 0.02 0.06 0.14 0.01 3,323,415.6
P/B — — — 0.00 0.00 5,467,194.27 209,183.97 0.03 0.09 0.22 0.01 810,911.2
EV/Sales — — — 18,653,132.50 897,142.28 2,672,584.05 1,041,058.12 (0.57) (0.16) (0.06) (0.33) 3,323,416.6
EV/FCF — — — (797,207.00) (97,069.19) (333,398.18) (830,915.25) 1.45 0.39 0.34 2.10 (294,083.9)
Cash, $m
Cash, $m Operating cash flow 0 (1) (1) 0 (1) (2) (5) (9) (13) (5) (5) +37.0%
Capex 0 0 0 0 0 — 0 (1) (2) (1) 0 +84.4%
Free cash flow 0 (1) (1) 0 (1) (2) (6) (10) (15) (6) (6) +39.0%
Balance, $m
Balance, $m Working capital 0 (1) 0 (1) 0 2 20 19 20 20 25 n/m
Net debt 0 0 0 0 0 0 (22) (16) (10) (9) (14) +75.6%
Shareholders’ equity 0 (1) 0 (1) (1) 0 22 21 24 23 28 n/m
Returns, %
Returns, % ROA (948.00) (646.29) (307.13) (266.78) (486.90) (765.70) (170.09) (15.92) (17.73) (19.71) (17.78) +928.3 pt
ROIC 0.00 0.00 (589.22) 0.00 0.00 (2,293.33) 0.00 (60.85) (26.30) (27.97) (26.67) (28.0) pt
ROE 771.30 235.58 591.39 372.60 302.59 2,637.37 (246.06) (21.04) (22.97) (25.69) (21.93) (797.0) pt
People
People Employees 3 3 9 3 3 3 46 44 52 50 — +36.7%
Revenue/emp, $m 0.00 0.00 0.00 0.01 0.02 0.08 0.09 0.55 0.67 0.73 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026

Sunshine Biopharma, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
APUS Apimeds Pharmaceuticals US, Inc. $4.1M — (loss-making) — — n/m −67.94% (below 0%: shrinking) — 0.00% Compare
RDHL Redhill Biopharma Ltd. $3.8M — (loss-making) — (loss-making) −90.32% (below 0%: shrinking) n/m −107.31% (below 0%: shrinking) (7.52%) 0.00% Compare
BTAIQ BioXcel Therapeutics, Inc. $2.3M — (loss-making) — (loss-making) +51.67% (above 0%: growing) n/m +51.51% (above 0%: growing) 87.91% (5,600.55%) Compare
PRFX PainReform Ltd. $2.3M — (loss-making) — (loss-making) — n/m +52.56% (above 0%: growing) 0.00% 0.00% Compare
AKAN Akanda Corp. $2.2M — — — — −472.01% (below 0%: shrinking) (197.87%) 0.00% Compare
SBFM Sunshine Biopharma, Inc. $2.1M — (loss-making) — (loss-making) −1.56% (below 0%: shrinking) n/m +49.38% (above 0%: growing) 26.20% (17.41%)
SXTC China SXT Pharmaceuticals, Inc. $2.0M — (loss-making) — (loss-making) −16.76% (below 0%: shrinking) +92.67% (above 0%: growing) −107.59% (below 0%: shrinking) 44.09% 0.00% Compare
PTPI Petros Pharmaceuticals, Inc. $1.0M — (loss-making) — (loss-making) +299.12% (above 0%: growing) n/m +71.27% (above 0%: growing) 359.80% 0.00% Compare
IMCC IM Cannabis Corp. $980.0K — (loss-making) — (loss-making) −40.28% (below 0%: shrinking) n/m −266.81% (below 0%: shrinking) 19.83% (27.54%) Compare
Median of peers $2.3M — — −16.76% — −87.62% 19.83% 0.00%

All 84 Drug Manufacturers Specialty & Generic stocks →

Sunshine Biopharma, Inc. (SBFM) Latest News

22 Oct

Impact 3 · · ACCESS Newswire

9 Oct

Impact 3 · · ACCESS Newswire

8 Oct

Impact 4 · · InvestorsHub
Impact 3 · · ACCESS Newswire

24 Sep

Impact 4 · · Zacks
Impact 3 · · ACCESS Newswire

16 Sep

Impact 4 ·
Impact 3 ·

31 Aug

Impact 4 ·

26 Aug

Impact 4 ·
Impact 4 ·

19 Aug

Impact 4 ·
Impact 3 ·

7 Aug

Impact 3 ·

4 Aug

Impact 4 ·
Impact 4 ·

28 Jul

Impact 4 ·

20 Jul

Impact 3 ·

25 Jun

Impact 3 · · ACCESS Newswire

1 Jun

Impact 3 · · ACCESS Newswire

29 May

Impact 4 · · ACCESS Newswire

21 May

Impact 3 · · ACCESS Newswire

19 May

Impact 3 · · ACCESS Newswire

18 May

Impact 3 · · ACCESS Newswire

6 Apr

Impact 3 · · ACCESS Newswire

28 Oct

Impact 4 · · ACCESS NewswireSimply Wall St.
Impact 4 · · ACCESS Newswire

20 Oct

Impact 4 · · ACCESS NewswireMT NewswiresMT NewswiresMT NewswiresMT NewswiresTipRanks

16 Oct

Impact 4 · · ACCESS Newswire

14 Oct

Impact 4 · · ACCESS Newswire
stockrow.com/SBFM · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com